BiomX (PHGE) Financials

BiomeX Inc (PHGE) is a company that specializes in the development and commercialization of novel therapies using the cutting-edge field of synthetic biology. As a biotechnology company, BiomeX is focused on harnessing the power of the human microbiome to treat a wide range of diseases. The company's strong financial performance is reflected in its income statement. BiomeX has consistently reported strong revenue growth, with total revenue reaching impressive figures. The company's net income from stockholders has also been robust, demonstrating its ability to generate profits. Additionally, BiomeX's gross profit has shown a steady increase, indicating its strong operational performance and efficient cost management.

Looking at BiomeX's balance sheet, it is evident that the company is in a strong financial position. BiomeX has a healthy stockholders equity, indicating that it has a solid foundation of assets held by the company's stockholders. Furthermore, the company's total assets have increased significantly over time, indicating its growth and expansion. BiomeX has managed its debt prudently, with a relatively low level of total debt. This is a positive sign for investors as it indicates the company's ability to handle its financial obligations. Additionally, the company has sufficient cash equivalents, providing it with liquidity and financial flexibility.

BiomeX's cash flow statement highlights its financial performance from an operational, investing, and financing perspective. The company has demonstrated strong operating cash flows, which are generated from its core business activities. This indicates that BiomeX is generating cash from its day-to-day operations, highlighting the company's profitability and ability to generate cash. BiomeX's investing cash flows reflect its investment in various assets and projects, showcasing its commitment to innovation and growth. The company's financing cash flows represent its activities related to raising capital, such as issuing stocks or taking on debt. Lastly, BiomeX's free cash flow, which is the cash left after subtracting capital expenditures from operating cash flow, has been positive, indicating the company's ability to generate excess cash and potentially invest in future growth initiatives.